Please assess the completion status of the following clinical trial:

Trial Title: Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient diagnosed with clinically definite MS according to the Polman criteria~* Age 18-65~* Have a RR disease course~* Have EDSS scores less than or equal to 5.5 {Kurtzke, 1983 #15}~* Have disease duration less than 20 years~* Fulfilled the TOUCH enrollment requirements and started on Tysabri monotherapy~* Signed informed consent~* None of the exclusion criteria~Exclusion Criteria:~* Primary progressive, secondary progressive, or progressive relapsing MS. Primary progressive, secondary progressive or progressive relapsing multiple sclerosis.~* A clinically significant infectious illness (e.g., cellulitis, abscess, pneumonia, septicemia) within 30 days prior to drug start.~* History of, or abnormal laboratory results indicative of, any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal, and/or other major disease that, in the opinion of the investigator, would preclude the administration of natalizumab for the duration of the study.~* History of severe allergic or anaphylactic reactions or known drug hypersensitivity.~* Abnormal blood tests, performed at the screening visit, which exceed any of the limits defined below:~* ALT/ SGPT, or AST/ SGOT \> three times the upper limit of normal (i.e., 3xULN).~* Total white blood cell (WBC) count \<2,300/mm3.~* Platelet count \<100,000/mm3.~* Creatinine \> 2xULN.~* Prothrombin time (PT) \> ULN.~* Any prior treatment during the 2 weeks prior to study screening with agents such as IFN-β, GA, IVIG, or on the following immunosuppressant therapies for less than 3 months: mitoxantrone, cyclophosphamide, cladribine, fludarabine, cyclosporine, azathioprine, methotrexate, Cellcept, etc.~* History of alcohol or drug abuse within 2 years prior to randomization.~* Female subjects who are not postmenopausal for at least 1 year, surgically sterile, or willing to practice effective contraception (as defined by the investigator) during the study. The rhythm method is not to be used as the sole method of contraception.~* Nursing mothers, pregnant women, and women planning to become pregnant while on study.~* Unwillingness or inability to comply with the requirements of this protocol including the presence of any condition (physical, mental, or social) that is likely to affect the subject's ability to comply with the study protocol.~* Any other reasons that, in the opinion of the Investigator, indicate that the subject is unsuitable for enrollment into this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: None): 63 patients with relapsing-remitting Multiple Sclerosis who are enrolled in the TOUCH program and have been taking Tysabri monotherapy for 2 years.
- 2 (Type: None): 22 age- and sex-matched normal controls who completed 1 year follow-up.

Based on this trial design, predict the completion outcome and termination type (if applicable).